Caption Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Caption Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-67,000	Closed	-$6.83M	–	1636
2023 Q2	$6.83M	Sell	67,000 -35,900	-35%	-$3.4M	0.12%	218
2023 Q1	$9.36M	Buy	+102,900	New	+$6.04M	0.18%	135
2022 Q4	–	Sell	-68,100	Closed	-$1.71M	–	1849
2022 Q3	$1.71M	Buy	+68,100	New	+$1.89M	0.02%	691
2022 Q2	–	Sell	-414,000	Closed	-$13.6M	–	1961
2022 Q1	$13.6M	Buy	414,000 +259,200	+167%	+$7.69M	0.16%	148
2021 Q4	$4.08M	Buy	154,800 +71,400	+86%	+$5.53M	0.05%	528
2021 Q3	$8.39M	Buy	+83,400	New	+$9.78M	0.1%	277
2020 Q3	–	Sell	-20,000	Closed	-$3.12M	–	1331
2020 Q2	$3.12M	Buy	20,000 +15,000	+300%	+$2.28M	0.1%	266
2020 Q1	$722K	Buy	+5,000	New	+$965K	0.04%	476
2019 Q4	–	Sell	-37,500	Closed	-$3.01M	–	1044
2019 Q3	$3.01M	Buy	+37,500	New	+$3.18M	0.16%	175

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Caption Management's RETA Position: Q4 2022 in Review

Caption Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 56,010 shares — an estimated $1.41M sold.

Caption Management first reported a position in RETA in Q4 2019 and held it in 6 quarters. The position peaked at $7.24M in Q4 2019. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Caption Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Caption Management sold 56,010 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $1.41M.
Caption Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 6 quarters.
Caption Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7.24M in Q4 2019.
168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Caption Management's 13F filing for Q4 2022, filed 14 Feb 2023.